APA (7th ed.) Citation

Wehling, C., Tönshoff, B., & Kirschfink, M. (2017). Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clinical & experimental immunology, 187(2), . https://doi.org/10.1111/cei.12890

Chicago Style (17th ed.) Citation

Wehling, Cyrill, Burkhard Tönshoff, and Michael Kirschfink. "Monitoring of Complement Activation Biomarkers and Eculizumab in Complement-mediated Renal Disorders." Clinical & Experimental Immunology 187, no. 2 (2017). https://doi.org/10.1111/cei.12890.

MLA (9th ed.) Citation

Wehling, Cyrill, et al. "Monitoring of Complement Activation Biomarkers and Eculizumab in Complement-mediated Renal Disorders." Clinical & Experimental Immunology, vol. 187, no. 2, 2017, https://doi.org/10.1111/cei.12890.